MTMasayoshi Tanaka

Masayoshi Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masayoshi Tanaka has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Dong Bin Back

    Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA

    2 shared publications
  • Bijay Parajuli

    Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo 409-3898, Japan

    1 shared publication
  • Eiji Shigetomi

    Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

    1 shared publication
  • Elga Esposito

    Neuroprotection Research Laboratories, Departments of Radiology and Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA

    1 shared publication
  • Eng H. Lo

    Massachusetts General Hospital and Harvard Medical School

    1 shared publication
  • Ester Licastro

    Division of Pharmacology, Department Neuroscience, School of Medicine, Federico II University of Naples, Naples, Italy

    1 shared publication

Latest Publications

  • Effects of mitochondrial O-GlcNAcylation in pericytes after mechanical injury

    by Ji Hyun Park, Dong Bin Back, Shuzhen Guo, Masayoshi Tanaka, Hajime Takase, Michael J. Whalen, Ken Arai, Kazuhide Hayakawa, Eng H. Lo


  • Therapeutic mitochondria treatment amplifies macrophage-mediated phagocytosis and recycling exocytosis

    by Masayoshi Tanaka, Shin Ishikane, Dong Bin Back, Ester Licastro, Fang Zhang, Ji Hyun Park, Elga Esposito, Giuseppe Pignataro, Takafumi Nakano, Yoshihiko Nakamura, et al.

    Therapeutic administration of mitochondria has been increasingly explored. However, how these administered mitochondria impact immune response remains to be fully addressed. In this proof-of-concept study, we show that extracellularly added mitochondria to cultured peritoneal macrophages increase phagocytosis and recycling exocytosis that amplifies neuroplasticity mediated by recycled mitochondria transfer. Macrophage activation markers such as Nos2 , Arg1 , and Cd163 were unchanged at 3 h post-treatment with mitochondria, but whole mitochondria or delivery of mRNAs extracted from whole mitochondria appeared to increase SQSTM1 protein and activate Nrf2-mediated phagocytosis in macrophages, whereas mitochondria treatment did not change the ability of phagocytosis in cultured microglia or astrocytes. Notably, the once engulfed mitochondria in macrophages appear to be released via Rab27a-mediated recycling pathway that were favorably incorporated in mechanically damaged neurons compared with healthy neurons, resulting in accelerating neurite extension in damaged neurons in a direct co-culture model. Altogether, these findings uncover unappreciated mechanisms that mitochondria-treated macrophages upregulate phagocytosis and recycling exocytosis, implicating that engineering mitochondria delivery to macrophages is a new therapeutic intervention to promote neurorecovery in CNS disorders.


  • Open Access

    Establishment and Use of Primary Cultured Astrocytes from Alexander Disease Model Mice

    by Yuto Kubota, Eiji Shigetomi, Kozo Saito, Youichi Shinozaki, Kenji Kobayashi, Masayoshi Tanaka, Bijay Parajuli, Kenji F. Tanaka, Schuichi Koizumi

    Alexander disease (AxD) is an intractable neurodegenerative disease caused by mutations in glial fibrillary acidic protein (GFAP), which is predominantly expressed in astrocytes. Thus, AxD is a primary astrocyte disease. However, it remains unclear how GFAP mutations affect astrocytes and cause AxD pathology. Three features are characteristic of AxD astrocytes in vivo: (1) Rosenthal fibers (RFs), the hallmark of AxD; (2) aberrant Ca2+ signals (AxCa); and (3) upregulation of disease-associated genes (AxGen). We established a primary culture system for astrocytes from an AxD transgenic mouse model, and used it to analyze the above features of AxD pathogenesis in astrocytes in vitro. We observed the formation of RFs in AxD primary cultures. The abundance of RFs was greater in AxD-transgene-homozygous compared with -hemizygous astrocytes, indicating a gene dosage effect, and this abundance increased with time in culture, indicating a developmental process effect. However, cultured AxD astrocytes did not exhibit changes in either AxCa or AxGen. We therefore conclude that RFs in astrocytes form via a cell-autonomous mechanism, whereas AxCa and AxGen are likely to occur via a non-cell-autonomous mechanism through interactions with other cells, such as neurons, microglia, and vascular cells. Although primary cultured AxD astrocytes are suitable for elucidating the mechanisms of RFs formation and for intervention studies, it should be noted that they cannot reflect the pathophysiology of non-cell-autonomous events in astrocytes.